Europe's AgriTech Leader Is Falling Behind—Here's What It Costs

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agricultural powerhouse. Think advanced greenhouses, world-class seed breeders, and a food production ecosystem that punches well above its weight. But a new report from Invest-NL, the Dutch national investment institution, suggests that reputation is starting to fray at the edges. Here's the uncomfortable truth: the country is great at inventing. It's just not great at turning those inventions into globally competitive businesses. ### The Numbers That Tell the Story The report, titled *Deep Dive Agrifood Biotech*, draws on interviews with more than 150 entrepreneurs, investors, researchers, and policymakers, plus investment data stretching from 2010 through April 2026. It focuses on three areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. One statistic stands out. The Netherlands accounts for 3.3% of BioTech startups worldwide, but only 1.3% of scale-ups. In plain terms, the country is excellent at starting things and far less successful at growing them. That gap between a strong start and a weak finish is where real money gets left on the table. If the barriers were addressed, Invest-NL estimates Dutch agrifood biotech companies could unlock roughly $18.5 billion in additional annual revenue by 2040. In a favorable scenario, annual revenues could climb to about $27 billion, compared with just $8.7–9.8 billion under current conditions. ### Three Weaknesses Holding Companies Back Invest-NL keeps hearing the same problems from founders and investors: - Too few promising technologies ever become scalable ventures - Regulatory and validation processes drag out market entry - Financing falls short of what's needed to reach industrial production The report is careful to note that the Netherlands doesn't need to manufacture everything at home. Instead, it should hold onto the strategically valuable pieces—knowledge, intellectual property, companies, and specialized capabilities—while leaning on European production networks where it makes sense. ### Ten Years to Say Yes Perhaps the most striking obstacle involves biological crop protection, where Dutch companies are developing alternatives to conventional chemical pesticides. Getting European regulatory approval for a new product in this space can take eight to ten years. The existing frameworks were largely built around chemical products, so they fit biological innovations poorly. As a result, some companies launch in Brazil or the United States first, where commercialization moves faster. Invest-NL warns that Europe could lose ground in a biological crop protection market that may expand seven- to tenfold by 2040. Food biotechnology runs into similar walls. Approval for novel ingredients can take one to three years longer in Europe than in the United States, and building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, favorable conditions could support about $8.7 billion in annual Dutch revenues by 2040—versus roughly $2.2 billion under existing policies. > Faster approvals shouldn't come at the expense of safety. The report argues regulators should offer earlier guidance, more predictable assessments, and chances for companies to validate products under real-world conditions. ### What This Means for Founders and Investors If you're building in this space, the message is fairly direct. Innovation isn't the bottleneck—commercialization is. The companies that win will be the ones that plan for regulatory timelines early, secure patient capital, and stay flexible about where they scale. For investors watching Europe, the gap between startup creation and scale-up growth is both a warning and an opening. The technology is there. What's missing is the machinery to turn it into revenue.